Lauren Veazey, MD
Family Medicine · Evansville, INNPI 1811208820
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 200 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,301, 6.3 times the $207 reported in 2019.
Across 200 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$775
- AstraZeneca$572
- Lilly USA, LLC$514
- Pfizer$281
- GSK$212
- Novo Nordisk$186
- plus $726 from 22 others
Across 22 payments — averaging $3089.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$22K
- GSK$18K
- Kowa Research Institute, Inc.$13K
- Pfizer$12K
- Novo Nordisk AS$4K
What the payments were for
- Food & beverage$3,22299%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $775 |
| AstraZeneca | 16 | $572 |
| Lilly USA, LLC | 35 | $514 |
| Pfizer | 15 | $281 |
| GSK | 12 | $212 |
| Novo Nordisk | 12 | $186 |
| Amgen | 7 | $159 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| Axsome Therapeutics, Inc. | 4 | $62 |
| Merck | 3 | $44 |
| Boehringer Ingelheim | 3 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Corium, LLC | 1 | $22 |
| Johnson & Johnson | 1 | $20 |
| Biogen | 1 | $20 |
| Shire North American Group Inc | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,267 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 67 | $113,992 |
| FarxigaDapagliflozin Propanediol | 46 | $56,106 |
| OzempicSemaglutide | 38 | $55,396 |
| JardianceEmpagliflozin | 43 | $53,961 |
| TrulicityDulaglutide | 20 | $46,780 |
| EliquisApixaban | 25 | $38,135 |
| RybelsusSemaglutide | 12 | $23,432 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $22,502 |
| VraylarCariprazine Hcl | 15 | $21,331 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $14,228 |
| LinzessLinaclotide | 15 | $9,560 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $8,329 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $6,559 |
| Bupropion XlBupropion Hcl | 57 | $3,678 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $3,178 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $514 | $160,77187 claims |
| Novo NordiskOzempic, Rybelsus | $186 | $78,82850 claims |
| AstraZenecaFarxiga | $572 | $56,10646 claims |
| Boehringer IngelheimJardiance | $40 | $53,96143 claims |
| PfizerEliquis | $281 | $38,13525 claims |
| AbbVieVraylar, Linzess, Synthroid | $775 | $32,68351 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $212 | $30,83136 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Evansville
- Anthony InzerelloEvansville$308K
- Carol GoodmanEvansville$123K
- David SchultzEvansville$22K
- J Christopher SartoreEvansville$19K
- David BrougherEvansville$18K
- Hubert ReyesEvansville$18K
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Joe BanksIndianapolis$294K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.